Status:
COMPLETED
A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD)
Lead Sponsor:
Epizon Pharma, Inc.
Conditions:
End-Stage Renal Disease (ESRD)
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Patients with End Stage Renal Disease (ESRD) are prone to early and accelerated vascular calcification. Both the prevalence and extent of the vascular calcification are predictive for cardiovascular m...
Detailed Description
Patients with End Stage Renal Disease (ESRD) are prone to early and accelerated vascular calcification. Both the prevalence and extent of the vascular calcification are predictive for cardiovascular m...
Eligibility Criteria
Inclusion
- Consenting subjects.
- Adult male and female who were diagnosed with stable ESRD.
- Subjects treated with maintenance hemodialysis at least 3 times a week for at least 3 months prior to the first dose of study drug.
- Clinically stable.
Exclusion
- Solid organ transplant.
- Malignancy.
- Severe infection requiring intravenous (IV) antibiotics.
- Any co-existing disease or condition that could have compromised the safety of study participants and/or the integrity of the study.
Key Trial Info
Start Date :
March 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2021
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT05285787
Start Date
March 1 2019
End Date
April 30 2021
Last Update
September 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Southeastern Clinical Research Institute, LLC
Augusta, Georgia, United States, 30904